CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
Gemcitabine Hydrochloride +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01195415
NCT01195415Phase 2Completed
CompareCT.gov

Cancer Stem Cells and Inhibition of Hedgehog Pathway Signaling in Advanced Pancreas Cancer: A Pilot Study of GDC-0449 in Combination With Gemcitabine

National Cancer Institute (NCI)·interventional·Posted Sep 6, 2010·Updated Aug 7, 2017

In Brief

A Phase 2 clinical trial evaluating Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, and 1 other intervention for Recurrent Pancreatic Carcinoma and Stage IV Pancreatic Cancer. Completed, enrolled 25 participants across 1 site.

Detailed Summary

This pilot clinical trial studies vismodegib and gemcitabine hydrochloride in treating patients with advanced pancreatic cancer. Vismodegib may stop the growth of pancreatic cancer by blocking blow flow to the tumor. Gemcitabine hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vismodegib and gemcitabine hydrochloride may kill more tumor cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 6, 2010
Enrollment StartJun 1, 2010
Primary CompletionJul 1, 2013
Study CompletionOct 10, 2014
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 15.8 years ago

Interventions

Gemcitabine Hydrochloridedrug

Given IV

Laboratory Biomarker Analysisother

Correlative studies

Vismodegibdrug

Given PO